Asia Pacific Pneumococcal Vaccine Market Size & Outlook
Asia Pacific pneumococcal vaccine market, 2018-2030 (US$M)
Related Markets
Asia Pacific pneumococcal vaccine market highlights
- The Asia Pacific pneumococcal vaccine market generated a revenue of USD 577.9 million in 2023.
- The market is expected to grow at a CAGR of 16.8% from 2024 to 2030.
- In terms of segment, pneumococcal conjugate vaccine was the largest revenue generating vaccine type in 2023.
- Pneumococcal Conjugate Vaccine is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 577.9 million |
| Market revenue in 2030 | USD 1,716.6 million |
| Growth rate | 16.8% (CAGR from 2023 to 2030) |
| Largest segment | Pneumococcal conjugate vaccine |
| Fastest growing segment | Pneumococcal Conjugate Vaccine |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 7.2% of the global pneumococcal vaccine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 379.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pneumococcal Vaccine Market Scope
Pneumococcal Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific pneumococcal vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 92.97% in 2023. Horizon Databook has segmented the Asia Pacific pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific pneumococcal vaccine market is witnessing significant growth driven by rising awareness about the importance of vaccination in preventing pneumococcal diseases. Several countries in the region are experiencing an increase in the prevalence of pneumococcal infections, leading to a higher demand for vaccines.
Manufacturers are actively expanding their presence in the Asia Pacific region, aiming to capitalize on the growing market opportunity. Local production facilities are being established to cater to the increasing demand for pneumococcal vaccines and reduce import dependency.
Government initiatives and vaccination programs aimed at immunizing children and adults against pneumococcal diseases are further driving market growth. These programs often involve subsidies or free vaccinations, making vaccines more accessible to the general population.
Reasons to subscribe to Asia Pacific pneumococcal vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific pneumococcal vaccine market databook
-
Our clientele includes a mix of pneumococcal vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific pneumococcal vaccine market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific pneumococcal vaccine market size, by country, 2018-2030 (US$M)
Asia Pacific Pneumococcal Vaccine Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
